Can Amphastar's Growth Momentum Fuel The Stock's Rise?

Shares of Amphastar Pharmaceuticals Inc. (AMPH) are down more than 42% from their all-time high of $67.66, recorded last August, and trade around $38.

Amphastar is a bio-pharmaceutical company developing and selling technically challenging generic and proprietary injectable, inhalation and intranasal products, and insulin active pharmaceutical ingredient, or insulin API products. Over 25 products are manufactured and sold, with the overwhelming majority being prescription pharmaceuticals.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com